Risks for ENANTA PHARMACEUTICALS INC (ENTA)

Here are some interesting risks from the recent filings of ENANTA PHARMACEUTICALS INC. Our algorithms work hard to highlight risks unique to this company.

We have not developed independently any approved products and we have limited clinical development experience, which makes it difficult to assess our ability to develop and commercialize

To date, our principal sources of revenue have been our collaboration agreements, including our c

urrent agreement with AbbVie. Future levels of royalties under the AbbVie agreement are uncertain. We have had no other products approved for commercial sale by us. Therefore, it is possible that we may incur operating losses in one or more years in the fu

ture, and our ability to achieve sustained profitability is unproven.

If we are required to suspend or discontinue clinical trials due to side effects or other safety risks associated with our product candidates, or if we are